ATE252905T1 - Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion - Google Patents

Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion

Info

Publication number
ATE252905T1
ATE252905T1 AT99919985T AT99919985T ATE252905T1 AT E252905 T1 ATE252905 T1 AT E252905T1 AT 99919985 T AT99919985 T AT 99919985T AT 99919985 T AT99919985 T AT 99919985T AT E252905 T1 ATE252905 T1 AT E252905T1
Authority
AT
Austria
Prior art keywords
renal function
composition containing
receptor antagonists
containing adenosine
diuretic
Prior art date
Application number
AT99919985T
Other languages
German (de)
English (en)
Inventor
Evan Beckman
Glenn Smits
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE252905T1 publication Critical patent/ATE252905T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99919985T 1998-04-24 1999-04-23 Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion ATE252905T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8302298P 1998-04-24 1998-04-24
US8363898P 1998-04-30 1998-04-30
PCT/US1999/008879 WO1999055339A1 (en) 1998-04-24 1999-04-23 Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function

Publications (1)

Publication Number Publication Date
ATE252905T1 true ATE252905T1 (de) 2003-11-15

Family

ID=26768857

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99919985T ATE252905T1 (de) 1998-04-24 1999-04-23 Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion

Country Status (8)

Country Link
EP (1) EP0994711B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002506463A (cg-RX-API-DMAC7.html)
AT (1) ATE252905T1 (cg-RX-API-DMAC7.html)
AU (1) AU3757999A (cg-RX-API-DMAC7.html)
CA (1) CA2295101C (cg-RX-API-DMAC7.html)
DE (1) DE69912375T2 (cg-RX-API-DMAC7.html)
ES (1) ES2211079T3 (cg-RX-API-DMAC7.html)
WO (1) WO1999055339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
NZ527917A (en) 1999-11-12 2005-03-24 Biogen Inc Polycycoalkylpurines as adenosine receptor antagonists
CN1859913A (zh) * 2003-04-25 2006-11-08 美国诺华卡迪亚公司 改善肾功能损伤个体多尿症的方法
EP1932529A1 (en) * 2003-04-25 2008-06-18 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20050239759A1 (en) * 2004-04-16 2005-10-27 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
WO2018153898A1 (de) * 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB998971A (en) * 1961-09-21 1965-07-21 Societé Civile Nova Improvements in or relating to medicines having a diuretic action
DE3305935C2 (de) * 1983-02-21 1985-05-30 Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn Kaliumneutrales Saluretikum mit antihypertensiver Wirkung
JPS61271226A (ja) * 1985-05-24 1986-12-01 Chemo Sero Therapeut Res Inst 利尿剤
JPH01254664A (ja) * 1988-04-04 1989-10-11 Daiichi Rajio Isotope Kenkyusho:Kk 新規ピリジニウム−テクネチウム９９ｍ錯体
JP2689023B2 (ja) * 1990-08-17 1997-12-10 バクスター、インターナショナル、インコーポレイテッド ヘモグロビンオリゴマーに基づく組成物及びその製造方法
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Also Published As

Publication number Publication date
EP0994711A1 (en) 2000-04-26
CA2295101A1 (en) 1999-11-04
DE69912375T2 (de) 2004-08-19
AU3757999A (en) 1999-11-16
ES2211079T3 (es) 2004-07-01
JP2009102399A (ja) 2009-05-14
DE69912375D1 (de) 2003-12-04
JP2002506463A (ja) 2002-02-26
WO1999055339A1 (en) 1999-11-04
WO1999055339A8 (en) 1999-12-29
EP0994711B1 (en) 2003-10-29
CA2295101C (en) 2009-06-30

Similar Documents

Publication Publication Date Title
DE59807232D1 (de) Verfahren zur prüfung von differentialschutzrelais/-systemen
ATE254095T1 (de) Selektive analoge der thyroidhormone
ID26964A (id) Komposisi dan metode untuk pengaturan pengaktifan limfosit
DE69708266D1 (de) Verfahren zur verfügungsstellung von inhaltsbetriebmitteln für telefonnetzbenutzers
ATE272631T1 (de) Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung
WO2000073307A3 (en) Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
ID26099A (id) Turunan amida dan antagonis nosiseptin
DE69835193D1 (de) Ringnetzwerk zur Verteilung von Schutzbetriebsmitteln durch funktionierende Kommunikationswege
DE69811706D1 (de) Polymerer brennstoffzusatz und verfahren zur herstellng desselben, und den zusatz enthaltender brennstoff
DE69838830D1 (de) Verfahren zur Reduzierung der Teilchengrösse
DE60207514D1 (de) Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten
DE69937831D1 (de) System und verfahren zum verwalten von anforderungen der benutzer in benutzer-anbieter-netzen
DE59811058D1 (de) Verfahren und kommunikationsnetz zur administrierung von teilnehmerdaten, insbesondere dienstedaten
DE3882822D1 (de) Verfahren zur betriebsmittellokalisierung in rechnernetzen.
IT8419675A0 (it) Antagonisti ricettori di adenosina
NL300405I2 (nl) Oestrogeenagonisten/-antagonisten
DE69928860D1 (de) System und Verfahren zur Auswahl von Servern für gespiegelte Sites
DE69837015D1 (de) Verfahren zur Stabilisierung und Messung von Troponinkomplexen
ATE296811T1 (de) Sulfonamid-derivate als 5-ht6 receptor antagonisten und verfahren zu ihrer herstellung
DE69922093D1 (de) Verfahren und System zum Verwalten von elektronischen Nachrichtenanhängen
DE69703227D1 (de) Differentielles GPS mit für bestimmte Teilnehmer abstufbarer Genauigkeit
EP0871771A4 (en) METHODS AND COMPOSITIONS FOR REALIZING AN APPROVED RECOMBINATION
DE60000307D1 (de) Verfahren und Vorrichtung zur Feststellung von Service Abweichungen in transaktionsorientierten Netzwerken
FI972308A7 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä si sältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
EP1082310A4 (en) Methods of identifying and using hla binding compounds as hla-agonists and antagonists

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties